HIV Drugs: Trigger of Autoimmunity
Implicit, severe immune sensitive reactions to the anti-HIV drug abacavir materialize through an autoimmune procedure, resulting from the design of drug-induced immunizing agent that are attacked by the body's immune system as all HIV Drugs blocks protein synthesis and enzymes which cause alteration in and enzyme synthesis, autoimmune deformities accrue in HIV Patient and proteins. Many times foreign myalgia’s and arthralgia’s occur in about 5% of patients with HIV, sometimes in association with HIV seroconversion. Many bone related diseases and HIV-associated arthralgia started progresses towards inflammatory joint disease and disorders because of HIV Treatment.
Related Conference of HIV Drugs: Trigger of Autoimmunity
7th World Congress on Neuroimmunology and Neuroinfectious Diseases
22nd International Conference on Allergic Diseases and Clinical Immunology
14th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
HIV Drugs: Trigger of Autoimmunity Conference Speakers
Recommended Sessions
- Autoimmune Diseases
- Autoimmunity and Transplantation
- Bioinformatics and Autoimmunity
- Cancer Immunology
- Clinical Autoimmunity: Current & Future Research
- Cytokine and Current Research
- Genetic Engineering & Therapeutics
- HIV Drugs: Trigger of Autoimmunity
- Immunometabolism and Autoimmunity
- Inherited Autoimmunity
- Lupus
- Molecular Immunology
- Ocular Autoimmunity
- Pathophysiology and Autoimmunity
- Pediatric Autoimmunity
Related Journals
Are you interested in
- Advances in Neuroimaging and Diagnostic Techniques - Neuroimmunology Congress 2026 (France)
- Advances in Neuroimmunology and Neuroinflammation - Neuroimmunology Congress 2026 (France)
- Artificial Intelligence and Data-Driven Approaches in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Autoimmune Neurological Disorders and Therapeutic Advances - Neuroimmunology Congress 2026 (France)
- Biomarkers and Precision Medicine in Neuroimmune Disorders - Neuroimmunology Congress 2026 (France)
- Case Studies and Clinical Practice in Neuroimmunology and Neuroinfectious Diseases - Neuroimmunology Congress 2026 (France)
- Clinical Trials and Drug Development in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- CNS Infections: Diagnosis, Management, and Prevention - Neuroimmunology Congress 2026 (France)
- Emerging Technologies and Future Directions in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Ethical Considerations and Future Perspectives in Neuroimmunology Research - Neuroimmunology Congress 2026 (France)
- Immunogenetics and Neuroimmune Interactions - Neuroimmunology Congress 2026 (France)
- Immunotherapy and Novel Treatment Strategies - Neuroimmunology Congress 2026 (France)
- Microbiome and the Gut-Brain-Immune Axis - Neuroimmunology Congress 2026 (France)
- Neurodegeneration and Immune System Interactions - Neuroimmunology Congress 2026 (France)
- Neuroimmunology in Pediatric Disorders - Neuroimmunology Congress 2026 (France)
- Neuroinfectious Diseases and Global Health Challenges - Neuroimmunology Congress 2026 (France)
- Public Health, Policy, and Global Collaboration in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Rehabilitation and Long-Term Management of Neuroimmune Disorders - Neuroimmunology Congress 2026 (France)
- Translational Research and Clinical Applications in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Young Researchers, Innovation, and Emerging Ideas - Neuroimmunology Congress 2026 (France)

